Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01717482|
Recruitment Status : Terminated (Poor accrual and funding ended)
First Posted : October 30, 2012
Results First Posted : June 19, 2019
Last Update Posted : June 19, 2019
|Condition or disease||Intervention/treatment||Phase|
|Lung Neoplasms Carcinoma, Non-Small-Cell Lung||Drug: Metformin Other: Placebo Comparator||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||6 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study of Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer|
|Study Start Date :||October 2012|
|Actual Primary Completion Date :||May 22, 2019|
|Actual Study Completion Date :||May 22, 2019|
Active Comparator: Metformin
Metformin 850mg twice a day
Other Name: Glucophage
Placebo Comparator: Observation
Standard of Care Observation
Other: Placebo Comparator
Standard of Care Observation
- Evaluate Feasibility of Patient Randomization, Accrual, and Tissue Collection for Study Conduction [ Time Frame: 2 years ]To evaluate the feasibility of patient randomization, accrual, and tissue collection in a pilot study of metformin versus observation following resection of stage IA-IIIA lung squamous cell cancer for patients by assessing the reasons patients decline randomization, tracking accrual numbers, and tracking collected tissue and reasons why tissue was not collected.
- Number of Participants With 2-year Recurrence Free Survival [ Time Frame: 4 years ]To compare the 2-year recurrence free survival (RFS) rate between metformin and observation.
- Measure Metformin Sensitivity in Induced Pluripotent Stem Cells (iPS) [ Time Frame: 4 years ]To develop the metformin sensitivity index based on iPS cell line metformin sensitivity measurements from the first 20 patients randomized to the metformin arm. We will then To apply the metformin sensitivity index on the remaining 25 patients randomized to metformin and the 45 observation patients (70 patients total) to compare the 2-year RFS rate between metformin-sensitive and metformin-not-sensitive patients.
- Number of Participants With Adverse Events as a Measure of Safety [ Time Frame: 4 years ]To compare participant adverse events between metformin and observation arms using CTCAE version 4.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01717482
|United States, Minnesota|
|Mayo Clinic in Rochester|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Dennis Wigle, MD, PhD||Mayo Clinic|